Wegovy Faces New Competition and Patent Challenges as Novo Nordisk Seeks Growth Beyond Blockbuster Weight Loss Drug

Impossibile aggiungere al carrello

Puoi avere soltanto 50 titoli nel carrello per il checkout.

Riprova più tardi

Rimozione dalla Lista desideri non riuscita.

Riprova più tardi

Non è stato possibile aggiungere il titolo alla Libreria

Per favore riprova

Non è stato possibile seguire il Podcast

Per favore riprova

Esecuzione del comando Non seguire più non riuscita

Wegovy Faces New Competition and Patent Challenges as Novo Nordisk Seeks Growth Beyond Blockbuster Weight Loss Drug

Ascolta gratuitamente

Vedi i dettagli del titolo

# Wegovy's New Chapter: Competition, Patents, and the Race for What's Next **Episode Description:** Wegovy built the modern weight-loss drug market—but can it stay on top? In this episode, we break down Novo Nordisk's pivotal moment as investors question the company's strategy beyond its blockbuster GLP-1 drugs, Wegovy and Ozempic. We cover the London investor meeting that sent Novo Nordisk shares tumbling up to 9%, the looming 2032 patent cliff for semaglutide, and why Eli Lilly's Zepbound is projected to outsell Wegovy by roughly $7 billion this year. We dive into the rise of oral Wegovy—now used by 1.5 million patients—and what its cash-pay-heavy adoption reveals about affordability and access in obesity treatment. You'll also hear about upcoming Wegovy data drops at the EASD conference in Milan, including real-world evidence from the Octane study, new findings on liver health (MASH), a higher 7.2mg dose, and early signals from the experimental drug CagriSema. Plus, we unpack a recent U.S. appeals court ruling on semaglutide shortages and what it means for compounding pharmacies and medical spas. Whether you're a patient, investor, healthcare provider, or just tracking the GLP-1 boom, this episode separates confirmed clinical and business developments from hype—so you know what's actually changing in the obesity drug landscape. **Topics covered:** Wegovy vs. Zepbound, Novo Nordisk earnings and strategy, semaglutide patent expiration, oral Wegovy pill rollout, CagriSema trial data, EASD Milan conference, Wegovy MASH liver studies, semaglutide shortage ruling, GLP-1 drug market competition. **Keywords:** Wegovy, Novo Nordisk, Ozemp Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai

Ancora nessuna recensione